223 related articles for article (PubMed ID: 21898832)
21. Unexpected N-acetylation of capreomycin by mycobacterial Eis enzymes.
Houghton JL; Green KD; Pricer RE; Mayhoub AS; Garneau-Tsodikova S
J Antimicrob Chemother; 2013 Apr; 68(4):800-5. PubMed ID: 23233486
[TBL] [Abstract][Full Text] [Related]
22. A random sequential mechanism of aminoglycoside acetylation by Mycobacterium tuberculosis Eis protein.
Tsodikov OV; Green KD; Garneau-Tsodikova S
PLoS One; 2014; 9(4):e92370. PubMed ID: 24699000
[TBL] [Abstract][Full Text] [Related]
23. Could mycobacterial MelF protein (Rv1936) be used as a potential drug target?
Mehta PK; Dharra R; Kulharia M
Future Microbiol; 2018 Sep; 13():1211-1214. PubMed ID: 30238773
[No Abstract] [Full Text] [Related]
24. Genotypic and phenotypic characteristics of aminoglycoside-resistant Mycobacterium tuberculosis isolates in Latvia.
Bauskenieks M; Pole I; Skenders G; Jansone I; Broka L; Nodieva A; Ozere I; Kalvisa A; Ranka R; Baumanis V
Diagn Microbiol Infect Dis; 2015 Mar; 81(3):177-82. PubMed ID: 25557624
[TBL] [Abstract][Full Text] [Related]
25. Discovery and development of inhibitors of acetyltransferase Eis to combat Mycobacterium tuberculosis.
Pang AH; Green KD; Tsodikov OV; Garneau-Tsodikova S
Methods Enzymol; 2023; 690():369-396. PubMed ID: 37858535
[TBL] [Abstract][Full Text] [Related]
26. Mycobacterium tuberculosis Low Molecular Weight Phosphatases (MPtpA and MPtpB): From Biological Insight to Inhibitors.
Fanzani L; Porta F; Meneghetti F; Villa S; Gelain A; Lucarelli AP; Parisini E
Curr Med Chem; 2015; 22(27):3110-32. PubMed ID: 26264920
[TBL] [Abstract][Full Text] [Related]
27. Fragment-based discovery of selective inhibitors of the Mycobacterium tuberculosis protein tyrosine phosphatase PtpA.
Rawls KA; Lang PT; Takeuchi J; Imamura S; Baguley TD; Grundner C; Alber T; Ellman JA
Bioorg Med Chem Lett; 2009 Dec; 19(24):6851-4. PubMed ID: 19889539
[TBL] [Abstract][Full Text] [Related]
28. A consequence of drug targeting of aminoacyl-tRNA synthetases in Mycobacteriumtuberculosis.
Ndagi U; Kumalo HM; Mhlongo NN
Chem Biol Drug Des; 2021 Sep; 98(3):421-434. PubMed ID: 33993612
[TBL] [Abstract][Full Text] [Related]
29. Acetylene-based analogues of thiolactomycin, active against Mycobacterium tuberculosis mtFabH fatty acid condensing enzyme.
Senior SJ; Illarionov PA; Gurcha SS; Campbell IB; Schaeffer ML; Minnikin DE; Besra GS
Bioorg Med Chem Lett; 2004 Jan; 14(2):373-6. PubMed ID: 14698162
[TBL] [Abstract][Full Text] [Related]
30. ESI-MS assay of M. tuberculosis cell wall antigen 85 enzymes permits substrate profiling and design of a mechanism-based inhibitor.
Barry CS; Backus KM; Barry CE; Davis BG
J Am Chem Soc; 2011 Aug; 133(34):13232-5. PubMed ID: 21776980
[TBL] [Abstract][Full Text] [Related]
31. Targeting Aminoglycoside Acetyltransferase Activity of Mycobacterium tuberculosis (H37Rv) Derived Eis (Enhanced Intracellular Survival) Protein with Quercetin.
Radhakrishnan L; Dani R; Navabshan I; Jamal S; Ahmed N
Protein J; 2024 Feb; 43(1):12-23. PubMed ID: 37932619
[TBL] [Abstract][Full Text] [Related]
32. Structural biology and biochemistry of cytochrome P450 systems in Mycobacterium tuberculosis.
McLean KJ; Munro AW
Drug Metab Rev; 2008; 40(3):427-46. PubMed ID: 18642141
[TBL] [Abstract][Full Text] [Related]
33. Elucidation of Mycobacterium tuberculosis type II dehydroquinase inhibitors using a fragment elaboration strategy.
Tran AT; West NP; Britton WJ; Payne RJ
ChemMedChem; 2012 Jun; 7(6):1031-43. PubMed ID: 22461418
[TBL] [Abstract][Full Text] [Related]
34. Studying aminoglycoside modification by the acetyltransferase class of resistance-causing enzymes via microarray.
Barrett OJ; Pushechnikov A; Wu M; Disney MD
Carbohydr Res; 2008 Nov; 343(17):2924-31. PubMed ID: 18774127
[TBL] [Abstract][Full Text] [Related]
35. Shortening the treatment of tuberculosis.
Mitchison DA
Nat Biotechnol; 2005 Feb; 23(2):187-8. PubMed ID: 15696148
[No Abstract] [Full Text] [Related]
36. New insight into the mechanism of action of and resistance to isoniazid: interaction of Mycobacterium tuberculosis enoyl-ACP reductase with INH-NADP.
Argyrou A; Vetting MW; Blanchard JS
J Am Chem Soc; 2007 Aug; 129(31):9582-3. PubMed ID: 17636923
[No Abstract] [Full Text] [Related]
37. DNA topoisomerase I and DNA gyrase as targets for TB therapy.
Nagaraja V; Godbole AA; Henderson SR; Maxwell A
Drug Discov Today; 2017 Mar; 22(3):510-518. PubMed ID: 27856347
[TBL] [Abstract][Full Text] [Related]
38. Characterization of DprE1-Mediated Benzothiazinone Resistance in Mycobacterium tuberculosis.
Foo CS; Lechartier B; Kolly GS; Boy-Röttger S; Neres J; Rybniker J; Lupien A; Sala C; Piton J; Cole ST
Antimicrob Agents Chemother; 2016 Nov; 60(11):6451-6459. PubMed ID: 27527085
[TBL] [Abstract][Full Text] [Related]
39. Identification of inhibitors targeting polyketide synthase 13 of Mycobacterium tuberculosis as antituberculosis drug leads.
Wang X; Zhao W; Wang B; Ding W; Guo H; Zhao H; Meng J; Liu S; Lu Y; Liu Y; Zhang D
Bioorg Chem; 2021 Sep; 114():105110. PubMed ID: 34175719
[TBL] [Abstract][Full Text] [Related]
40. Characterization of 2-hydroxy-1-naphthaldehyde isonicotinoyl hydrazone as a novel inhibitor of methionine aminopeptidases from Mycobacterium tuberculosis.
John SF; Aniemeke E; Ha NP; Chong CR; Gu P; Zhou J; Zhang Y; Graviss EA; Liu JO; Olaleye OA
Tuberculosis (Edinb); 2016 Dec; 101S():S73-S77. PubMed ID: 27856197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
